NCT06488170Active, not recruiting
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting - Light Version
Source: ClinicalTrials.gov · Last updated 24 Jun 2025
Brief summary (registry, in English)
The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe plaque psoriasis in accordance with the summary of product characteristics (SmPC).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 42 (actual)
- First submitted
- 28 Jun 2024
- Start date
- 4 Apr 2024
- Primary completion date
- Jan 2026
- Lead sponsor
- Almirall, S.A.
- Diseases
- Psoriasis
- NCT number
- NCT06488170
What you commit to
- Study type: Observational
- Participants enrolled: 42
- From 4 Apr 2024 to the primary completion date, Jan 2026
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Exposure to \>= 3 biologics prior to inclusion.
Other
- Participant unable or unwilling to comply with the requirements of the study.
- Participant who should not participate in the study for any reason at the discretion of the treating physician.
- Participants participating in a simultaneous clinical trial.
- Any contraindication against the use of Tildrakizumab according to the SmPC.
- Participant dependent on the investigator, e.g. as employee
Who the study is looking for
- Participant with diagnosis of moderate or severe chronic plaque PSO documented in the medical chart.
- Participant who needs systemic biologic therapy and qualifies for treatment with an IL-23p19 inhibitor. Tildrakizumab must be the anti-Il-23p19 selected therapy before including the patient in the study.
- Participant aged greater than or equal to (\>=) 18 years at Inclusion.
- Written informed consent.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Ostrava Coordinator of this site? Confirm its status | Ostrava | Czechia | Unknown status |
| Fakultní nemocnice Plzeň, with its registred seat at Edvarda Beneše Coordinator of this site? Confirm its status | Pilsen | Czechia | Unknown status |
| University Hospital Bulovka Coordinator of this site? Confirm its status | Prague | Czechia | Unknown status |
| University Hospital in Motol Coordinator of this site? Confirm its status | Prague | Czechia | Unknown status |
| University Hospital Kralovske Vinohrady Coordinator of this site? Confirm its status | Prague | Czechia | Unknown status |
| General University Hospital Prague Coordinator of this site? Confirm its status | Prague | Czechia | Unknown status |
| Masarykova hospital Ústí nad Labem Coordinator of this site? Confirm its status | Ústí nad Labem | Czechia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.